BERLIN, June 17 (Reuters) - U.S. pharmaceutical company Moderna (MRNA.O), opens new tab is interested ‌in investing in production facilities in Germany, with an eye on ⁠plants that its German rival ...

A new comprehensive study of billions of mRNA vaccine shots confirm that they are safe and effective and that serious side effects are rare.

A comprehensive new review published in The Lancet affirms that currently approved mRNA vaccines are safe and highly ...

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

It's not as if Pfizer has been ignoring its march toward some key patent cliff, for the record. It's been acting. In November 2025, the drugmaker completed its acquisition of Metsera, garnering its ...

The FDA has expanded the label for Pfizer’s subcutaneous hemophilia drug Hympavzi, now including patients age 6 and older who have hemophilia A or B. The anti-tissue factor pathway inhibitor was ...

NEW YORK, June 6 (Reuters) - Pfizer (PFE.N), opens new tab presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its purchase of Metsera last year ...

In a 32-week extension of its phase 2b VESPER-1 study, patients with obesity or overweight who escalated from placebo to a 2.4 mg weekly dose of berobenatide achieved a non-placebo-adjusted weight ...

U.S. vaccine maker Moderna (MRNA) is exploring investments in manufacturing facilities in Germany and is particularly interested in acquiring sites that rival BioNTech (BNTX) plans to shut down as ...

Pfizer (PFE) yields nearly 7%, but free cash flow covered only 93% of dividends in 2025, leaving a dangerously thin buffer. CEO Albert Bourla publicly committed to growing the dividend as Pfizer ...

This week, the pharma giants Roche Holding AG (RHHBY) and Pfizer Inc. (PFE) both gave presentations at the American Diabetes Association (“ADA”) to discuss the latest results and outline paths to ...

Lexicon Pharmaceuticals operates as a contender among biotech stocks by utilizing gene science to develop treatments for chronic conditions. The company primarily focuses on its commercial product, ...